Montelukast for Regulating the Balance on Peripheral Blood Th1/Th2 Cells in Patients with Allergic Rhinitis

Objective To explore the clinical efficacy of Montelukast treating the allergic rhinitis,and further to explore the impact on regulating peripheral blood Th1/Th2 cell balance function,and further to study the immune mechanism of Montelukast treating allergic rhinitis.Methods 92 patients with allergic rhinitis were randomly divided into budesonide group and the budesonide group resepectively 46 cases.And at the same period to choose 30 cases healthy subjects as normal control group,using ELISA to check the serum IFN-γ,IL-4 levels.Results The efficacy of montelukast group was significantly better than the control group(P0.05).After treatment,the clinical symptoms such as nasal congestion,nasal itching,runny nose,sneezing,and symptoms score significantly was lower than before treatment,and the montelukast group improved significantly better than the budesonide group(P0.05).IL-4 in patients with allergic rhinitis were significantly higher than the normal control group,and the serum IFN-γ levels were significantly lower than the normal control group(P0.05).After the treatment,the serum IL-4 levels in montelukast group compared with before treatment significantly decreased(P0.01),IFN-γ significantly increased(P0.05),and the serum IL-4,IFN-γ levels of montelukast group change than the budesonide group was significantly(P0.05).Conclusion Montelukast superior to the budesonide of treating allergic rhinitis,and it can significantly improve the clinical symptoms.It may be related to regulating the balance of Th1/Th2 cell function disorder in patients with allergic rhinitis.